Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.69 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2759959 | 0.95 | SIGMAR1 (0.68) | SIGMAR1PARP15PARP10PARP2SMN1; SMN2 | |
| SCHEMBL2566683 | 0.93 | SIGMAR1 (0.78) | SIGMAR1PARP15PARP10PARP2SMN1; SMN2 | |
| SCHEMBL31434575 | 0.86 | SIGMAR1 (0.68) | SIGMAR1PARP15PARP10PARP2SMN1; SMN2 | |
| SCHEMBL1674342 | 0.83 | SIGMAR1 (0.73) | SIGMAR1SMN1; SMN2PTGS2LTA4HPTGS1 | |
| SCHEMBL10509231 | 0.83 | SIGMAR1 (0.68) | SIGMAR1PARP15PARP10SMN1; SMN2CYP19A1 | |
| SCHEMBL3190605 | 0.83 | SIGMAR1 (0.61) | SIGMAR1SMN1; SMN2PTGS2LTA4HPTGS1 | |
| SCHEMBL7362580 | 0.82 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL27935608 | 0.81 | SIGMAR1 (0.70) | SIGMAR1 | |
| SCHEMBL27935609 | 0.81 | SIGMAR1 (0.70) | SIGMAR1PTGS2LTA4HPTGS1HRH3 | |
| SCHEMBL5548803 | 0.80 | SIGMAR1 (0.61) | SIGMAR1PARP15PARP10PARP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382218-A1 | DELTA-5-DESATURASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010087467-A1 | DELTA-5-DESATURASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | WO | disclosed |
| US-20100190747-A1 | Fused ring compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190747-A1 | Fused ring compound and use thereof | CYP46A1, LTB4R2, PTGES | SIGMAR1 3012/4885PARP15 1905/4885PARP10 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.